Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
1.080
0.00 (0.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
Atai Life Sciences Employees
Atai Life Sciences had 83 employees as of December 31, 2023. The number of employees decreased by 50 or -37.59% compared to the previous year.
Employees
83
Change (1Y)
-50
Growth (1Y)
-37.59%
Revenue / Employee
$4,554
Profits / Employee
-$699,651
Market Cap
181.22M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 83 | -50 | -37.59% |
Dec 31, 2022 | 133 | 46 | 52.87% |
Dec 31, 2021 | 87 | 52 | 148.57% |
Dec 31, 2020 | 35 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Accuray | 987 |
Cellectis | 221 |
NeuroPace | 171 |
Profound Medical | 131 |
Vaxart | 109 |
Cabaletta Bio | 103 |
DiaMedica Therapeutics | 19 |
Atossa Therapeutics | 12 |
ATAI News
- 4 weeks ago - IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG - GlobeNewsWire
- 2 months ago - atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Psychedelic Stock Deep Dive: Atai Life Sciences - Seeking Alpha
- 2 months ago - atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Psychedelic drug contender stocks drop after FDA rejects MDMA treatment - Market Watch
- 3 months ago - atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference - GlobeNewsWire
- 4 months ago - atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - GlobeNewsWire
- 4 months ago - atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a - GlobeNewsWire